Cerluten®
In addition to visual EEG assessment, the alpha index was calculated in patients before and after treat-
ment (Table 6). It was found that under the influence of the treatment, there was a significant increase
in the alpha index in the patients of the study groups. The value of the alpha index was significantly
higher in the group of patients after treatment with CERLUTEN® as compared to the values in other
groups. However, the degree of change in the alpha index in patients receiving different treatments
was not the same.
CONCLUSION
Based on the data obtained, it is legitimate to conclude that the inclusion of reserve capacities of the
cerebral cortex with the help of CERLUTEN® improves the integral functions of the brain.
Thus, the clinical study results indicate the effectiveness and feasibility of using CERLUTEN® in the
complex treatment and prevention of diseases of the central nervous system of various origins.
CERLUTEN® does not cause side effects, complications, or drug dependence; clinical trials have iden-
tified no contraindications.
CERLUTEN®can be used for therapeutic and prophylactic purposes, combined with any means of
symptomatic therapy used in neurological practice (vascular, nootropic, absorbable, anticonvulsant,
vitamins, etc.).
REFERENCES
1. Kovalev G.V. Nootropic medicines. – Volgograd: Nizh.-Volzh. Publishing house, 1990. – 368 p.
2. Treatment of nervous diseases: Translated from English/ Edited by V.K.Viderholt. – M.: Medicine,
1984. – 560 p.
3. Mashkovsky M.D., Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gam-
ta”, 1993.
RECOMMENDATIONS FOR USE
CERLUTEN® is recommended to accelerate the recovery of brain functions after traumatic brain in-
jury, strokes, intellectual-mnestic disorders, exposure of the body to various extreme factors. It is also
recommended for the elderly to maintain mental performance.
CERLUTEN® is recommended to be taken 10-15 minutes before meals, 1-3 tablets or capsules 2-3
times a day for 10-20 days.
A second course is advised in 3 - 6 months.
There were no contraindications or side effects observed when using CERLUTEN®.
Responsible executor: A.A. Veretenko Executor: O.U. Raigorodsky
Deputy Director of the LLC «Medical Center Chief Physician of the LLC «Medical Center of
of the St. Petersburg Institute of Bioregulation the St. Petersburg Institute of Bioregulation
and Gerontology, SZO RAMS» for clinical work, and Gerontology, SZO RAMS», Candidate of
Candidate of Medical Sciences (PhD in Medical Medical Sciences (PhD in Medical Science)
Science), Associate Professor
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.